Kuros Biosciences
Kuros Biosciences AG is a Swiss-based company focused on the development of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off of the Eidgenössische Technische Hochschule Zürich (ETHZ), Kuros has developed a pipeline of products based upon its proprietary technology platforms. These platforms were developed from work carried out at ETHZ, at the University of Zürich and at the California Institute of Technology (CalTech). In addition, in early 2017 Kuros acquired Xpand Biotechnology to gain access to its MagnetOs family of bone graft substitutes and the associated surface science technology. Kuros has attractive commercial prospects in key market segments as well as an EU hub for future clinical and distribution operations. The company is in transition to commercial stage with one product having marketing approval in the EU and US and further product expected to achieve EU approval this year. MagnetOs is approved for sale in the EU for orthopedic, spine and dental applications, and in the US for posterolateral spinal fusion. In addition, a putty formulation is being prepared for submission in the EU and the US in the second half of this year. Neuroseal, a novel biomaterial for dural sealing, is Kuros’ second product and currently under review for CE marking in the EU. Kuros has also assembled a pipeline of clinical stage programs in various stages of development and amassed significant clinical and preclinical data in a number of indications and applications primarily in the area of orthobiologics. The Company has enrolled over 600 patients in multinational clinical trials, and has generated promising safety and efficacy in a number of significant indications.
Kuros Biosciences AG is a Swiss-based company focused on the development of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off of the Eidgenössische Technische Hochschule Zürich (ETHZ), Kuros has developed a pipeline of products based upon its proprietary technology platforms. These platforms were developed from work carried out at ETHZ, at the University of Zürich and at the California Institute of Technology (CalTech). In addition, in early 2017 Kuros acquired Xpand Biotechnology to gain access to its MagnetOs family of bone graft substitutes and the associated surface science technology. Kuros has attractive commercial prospects in key market segments as well as an EU hub for future clinical and distribution operations. The company is in transition to commercial stage with one product having marketing approval in the EU and US and further product expected to achieve EU approval this year. MagnetOs is approved for sale in the EU for orthopedic, spine and dental applications, and in the US for posterolateral spinal fusion. In addition, a putty formulation is being prepared for submission in the EU and the US in the second half of this year. Neuroseal, a novel biomaterial for dural sealing, is Kuros’ second product and currently under review for CE marking in the EU. Kuros has also assembled a pipeline of clinical stage programs in various stages of development and amassed significant clinical and preclinical data in a number of indications and applications primarily in the area of orthobiologics. The Company has enrolled over 600 patients in multinational clinical trials, and has generated promising safety and efficacy in a number of significant indications.
Kuros Biosciences has raised $6.2M across 1 round. Its most recent round was a Post-IPO Equity of $6.2M in Sep 2022. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Kuros Biosciences is featured in
Similar companies
arcoris bio provides spatial multiomics solutions focused on transforming biomedical research and diagnostics.
HemostOD manufactures platelets on-demand from engineered stem cells.
DropGen focuses on cutting-edge lab technology that enables the precise control of very small droplets within patterned microarrays.
Pharvaris is a clinical-stage company working on bringing a new oral bradykinin B2 receptor antagonist to patients as an alternative to injected therapies for hereditary angioedema and other related conditions. Their lead drug candidate, PHA121, is a potent small-molecule bradykinin B2 receptor antagonist currently in Phase 1 clinical study. The co-founders of Pharvaris include the inventor of icatibant and key leaders from Jerini AG, who developed icatibant for HAE treatment, now marketed as Firazyr® by Takeda.
Sequana Medical is a Swiss medical device company providing implantable pump systems to manage fluid balance within the body. This system is designed to move excess fluid to the bladder, where it is passed naturally from the body through normal urination. Sequana Medical’s first product, the Alfapump System, is an innovative solution for the management of ascites. Ascites is a fluid that collects in the abdominal cavity in people with advanced liver disease, certain cancers, or congestive heart failure. Alfapump System was the first and only system for the automatic and continual removal of ascites. Sequana Medical was founded in 2006 and is based in Zurich, Switzerland.
A Swiss medical technology business called Medyria develops systems for endovascular catheter navigation and sensing. The goal of Medyria is to speed up, secure, and improve catheter-based treatments. In Technopark in Winterthur, Switzerland, Medyria is headquartered.
SEITO Biologics is a new biotechnology startup in the preclinical stage, focused on developing creative immunotherapies for autoimmune and chronic inflammatory conditions.
ReproNovo is changing the landscape of reproductive medicine and women's health by pushing boundaries and introducing cutting-edge treatments for infertility and uterine conditions such as adenomyosis. Our experienced international team is well-versed in reproductive medicine, drug development, regulatory strategy, and business development, with a successful history of bringing new therapies to the market. Backed by top investors, including Jeito Capital and M Ventures, our headquarters are in Lausanne, Switzerland, with development teams in Copenhagen, Denmark and Barcelona, Spain. Contact us at info@repronovo.com for more information. Meet our leadership team: CEO & Co-Founder Jean Duvall, Chief Scientific & Medical Officer & Co-Founder Joan-Carles Arce, and Chief Financial Officer & Co-Founder BingMei Hao.
HAYA Therapeutics is a company that develops RNA-based treatments for heart failure. Their therapies target a specific regulator of fibrosis in the heart, known as long noncoding RNA, in order to block myocardial fibrosis and effectively treat heart failure.
Granite Bio is a biotechnology company working on creating new antibodies for the treatment of inflammatory, autoimmune, and fibrotic diseases.
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new therapies and harnessing the potential of Sonelokimab, a novel investigational Nanobody®, to transform results for patients experiencing inflammation.
SamanTree Medical is a pioneering medical device company from Switzerland that offers an innovative imaging solution that has the potential to enhance patient care and improve the results of cancer surgery. Their solution, which is based on confocal microscopy, allows surgeons to have precise and comprehensive control over margins during surgery.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.